Evonik and Ethris have formed a strategic partnership to develop and market a novel lipid nanoparticle (LNP) platform for nucleic acid delivery.
Combining Evonik’s formulation and manufacturing expertise with Ethris’ SNaP LNP technology, the collaboration aims to improve stability, targeting, and delivery of RNA therapies and vaccines, expanding options for pharma partners globally.